Haisco has also signed an agreement to be the exclusive distributor of Regentis Biomaterials' hydrogel, developed to treat cartilage damage, in China.
Regentis Biomaterials, an Israel-based company developing treatments for damaged cartilage, has closed a $15m series D round led by pharmaceutical company Haisco.
Haisco invested alongside Generali Investment, a subsidiary of insurance group Generali, as well as venture capital fund Medica Venture Partners, VC firm SCP Vitalife Partners and T³, the technology transfer office of Israeli university Technion.
Founded in 2004, Regentis has developed a hydrogel called GelrinC to regenerate tissue in order to treat articular cartilage lesions.
GelrinC, based on…
